medigraphic.com
Colegio de Medicina Interna de México.

2009, Number 4

<< Back Next >>

Med Int Mex 2009; 25 (4)

Cardiac power as prognostic marker in cardiogenic shock in acute myocardial infarction

Esquivel MCG, Chávez LL, García EFA, Ramírez GJR, Oyervides JVM, García CIL, Camacho CR

Language: Spanish
References: 16
Page: 263-269
PDF size: 47.88 Kb.


ABSTRACT

Antecedents: The cardiogenic shock (CCH) occurs in about 5 to 15% of patients with acute myocardial infarction (AMI) with high mortality. The power-cardiac (CP) is to haemodynamic parameter that represents the ability of the heart ace to pump, according chronotropism predictor of morbidity and mortality.
Objective: To determine the usefulness of the (PC) in patients with CCH as factors of mortality at 6, 24 hours and 30 day.
Design: retrospective, longitudinal, observational, descriptive. Instead of carrying out the study: Unidad de Cuidados Coronarios, Unidad Médica de Alta Especialidad 71, Torreón, Coahuila, México.
Material and Methods: Cardiac power calculation (CP = MAP x OC / 451) to 47 subjects of 128 carriers of AMI having haemodynamic monitoring and using a bivariate analysis was analyzed the degree of association between CP and mortality at 6 hours, 24 hours and 30 days.
Results: Of 128 patients with AMI, 26 (20.3%) were of HCC. The mortality of the sample examined was 20.31% (n = 128). The mortality of the group with a diagnosis of cardiogenic shock was 57.69% (n = 26). The association of CP and mortality at 30 days was OR 1.46 CI 0.98-2.17 (p = 0.58), mortality to 24 hours OR 2.61 CI 0.99-6.8 (p = 0.004).
Conclusions: The CP is an independent variable predicting mortality at 30 days and 24 hours.


REFERENCES

  1. Hasdai D, Holmes D, Califf R, et al. Cardiogenic shock complicating acute myocardial infarction: Predictors of death. Am Heart J 1999;138:21-31.

  2. Califf RM, Bengtson JR. Cardiogenic shock. N Engl J Med 1994;330:1724-31.

  3. Holmes DR, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. J Am Coll Cardiol 1995;26:668-74.

  4. Por el Grupo Cooperativo RENASICA. Arch Cardiol Mex 2002;72:S45-S64.

  5. García-Castillo A, Jerjes-Sánchez C, Martinez-Bermúdez P, Azpiri-López JR, y col. Registro Mexicano de Síndromes Coronarios Agudos (RENASICA II). Arch Cardiol Mex 2005;7:S6-S19.

  6. Chuquiure E. Consideraciones fi siopatológicas actuales del choque cardiogénico asociado a los síndromes isquémicos coronarios agudos. Arch Cardiol Mex 2006;76 (S2):258-60.

  7. Fincke R, Hochman J, Lowe A, et al. Cardiac Power is the Strongest Hemodynamic Correlated of Mortality in Cardiogenic Shock: A Report From the SHOCK Trial Registry. J Am Coll Cardiol 2004;44(2):340-48.

  8. Lupi E, Chuquiure E, González P, y col. El poder cardiaco: un instrumento del pasado, posiblemente una herramienta moderna en la valoración: clínica, terapéutica y pronóstica del choque cardiogénico por síndrome isquémico coronario agudo. Arch Cardiol Mex 2006;76(1):95-108.

  9. Cotter G, Williams SG, Vered Z, Tan LB. Role of cardiac power en heart failure. Curr Opin Cardiol 2003;18:215-22.

  10. Cooke G, Marshall P, Al-Timman J, et al. Physiological cardiac reserve: development of a non-invasive method and first estimates in man. Heart 1998;79:289-94.

  11. Kurl S, Laukkanen J, Niskanen L, et al. Cardiac Power During Exercise and the Risk of Stroke in Men. Stroke 2005;36: 820-824.

  12. Armstrong G, Carlier S, Fukamachi K, Thomas J, Marwick T. Estimation of cardiac reserve by peak power: validation and initial application of a simplifi ed index. Heart 1999;82(3):357-64.

  13. Tan LB. Evaluation of cardiac dysfunction, cardiac reserve and inotropic response. Postgrad Med J 1991;67(suppl 1):S10-20.

  14. Mendoza DD, Cooper HA, Panza JA. Cardiac power output predicts mortality across a broad spectrum of patients with acute cardiac disease. Am Heart J 2007;153:366-70.

  15. Cohen A, Tabet J, Logeart D, et al. A non-invasively determined surrogate of cardiac power (circulatory power) at peak exercise is a powerful prognostic factor in chronic heart failure. Eur Heart J 2002;23:806-14.

  16. Lupi HE, González PH, Juárez UH, y col. La meta de la reperfusión en los síndromes isquémicos coronarios con elevación de segmento ST. “Lo que hay más allá del fl ujo TIMI 3 epicárdico”. Arch Cardiol Mex 2002;72:311-49.




2020     |     www.medigraphic.com